Page 179 - Read Online
P. 179

Bradshaw et al. Vessel Plus 2023;7:35   https://dx.doi.org/10.20517/2574-1209.2023.121                                                                                Page 13 of 21


                              Table 2. Published research demonstrating or relating to the importance of the K ATP  channel in neuroprotection

                              Reference (author, year)      Model                  Findings

                                                     [145]
                              Garcia de Arriba et al., 1999  Rat neocortical tissue  ATP-dependent potassium channels were neuroprotective during hypoxia in rat neocortical tissues
                                              [146]
                              Domoki et al., 1999           Swine model            Diazoxide preserved neuronal-vascular function after cerebral ischemia in newborn pigs
                                              [144]
                              Debska et al., 2001           Rat hippocampal tissue  Potassium channel openers depolarized hippocampal mitochondria
                                             [28]
                              Shake et al., 2001            Canine model           Intravenous diazoxide was neuroprotective in dogs undergoing cardiopulmonary bypass
                                                [29]
                              Caparrelli et al., 2002       Rabbit model           Diazoxide pretreatment resulted in improved neurologic outcomes, and the mechanism appeared to be due to the K ATP  channel activity
                                               [148]
                              Teshima et al., 2003          Cerebellar neurons     MitoK ATP  channel openers inhibited apoptosis by preserving mitochondrial inner membrane potential
                                               [147]
                              Barreiro et al., 2006         Canine model           Pretreatment with diazoxide plus HCA led to improved neurologic outcomes versus HCA alone
                                                [151]
                              Yamanaka et al., 2018         Mouse model            Diazoxide and EPO were synergistically protective of the spinal cord after ischemia with upregulation of a common receptor
                                                [152]
                              Yamanaka et al., 2019         Mouse model            Diazoxide and EPO were synergistically protective of the spinal cord after ischemia via upregulation of NGF
                                                [150]
                              Yamanaka et al., 2019         Mouse model            Oral diazoxide preserved motor function in spinal cord ischemia-reperfusion injury by the STAT3 pathway
                                            [153]
                              Ikeno et al., 2023            Mouse model            Direct and indirect activation of mitoK   channels were involved pharmacological spinal cord protection with motor function preservation
                                                                                                                   ATP
                              EPO: Erythropoietin; NGF: nerve growth factor; STAT3: signal transducer and activator of transcription; HCA: hypothermic circulatory arrest.



                              The mechanism of diazoxide for neuroprotection is similar to one of many proposed for its cardioprotective action. Diazoxide is a K  channel opener that
                                                                                                                                                                                        ATP
                              inhibits complex II and maintains mitochondrial membrane potential. This prevents mitochondrial dysfunction and cell death following DHCA and injury
                              due to N-methyl-D-aspartate (NMDA) excitotoxicity via unique pathways and could be utilized to produce synergistic benefit with NMDA blockade during
                              cardiac surgery with DHCA [Figure 5] .
                                                                         [149]


                              Early studies on neuroprotection focused on the brain cortex, but more contemporary work evaluated K  channels and protection of the spinal cord, which is
                                                                                                                                                    ATP
                              applicable to cardiac surgical procedures on the descending aorta that have a known complication of paraplegia from spinal ischemia. Diazoxide attenuated
                              spinal cord ischemia-reperfusion injury, and motor function after spinal cord ischemia was improved in a mouse model with diazoxide compared to controls,
                              an action that appeared to be associated with expression of the signaling transducer and activator of transcription (STAT) 3 pathway . These results have
                                                                                                                                                                                         [150]
                              been confirmed by several others that have demonstrated the potential of diazoxide to reduce spinal cord injury following ischemia                  [151-153] .



                              Further work is needed to characterize the mechanisms involved in neuroprotection provided by diazoxide and its potential use in cardiac surgery.



                              FUTURE DIRECTIONS

                              Future work will further advance the understanding of the function and potential of K  channels for the benefit of patients undergoing cardiac surgery.
                                                                                                                                    ATP
                              Perhaps one of the most anticipated future endeavors is a large clinical trial using diazoxide as an additive to cardioplegia. While the use of diazoxide for
   174   175   176   177   178   179   180   181   182   183   184